Analysis of evolocumab for hypercholesterolaemia, February 2023
Page last updated: 20 July 2023
Drug utilisation sub-committee (DUSC)
February 2023
Abstract
Purpose
To review the utilisation of evolocumab for all of its listed Pharmaceutical Benefits Scheme (PBS) indications: homozygous familial hypercholesterolaemia, heterozygous familial hypercholesterolaemia and non-familial hypercholesterolaemia.
Date of listing on the PBS
Evolocumab was first listed on the PBS on 1 December 2016.
Data Source / methodology
Data extracted from the PBS and Authorities databases maintained by the Department of Health and Aged Care, processed by Services Australia were used for the analyses.
Key Findings
- In 2021, 6,119 patients were treated with evolocumab and supplied 48,483 prescriptions.
- There was a greater proportion of patients treated with evolocumab for non-familial hypercholesterolaemia compared to familial hypercholesterolaemia.
- Utilisation of evolocumab for non-familial hypercholesterolaemia was lower than estimated.
- In 2021, 80.7% of patients were consistently supplied evolocumab for the same indication based on the PBS item code compared to 70.5% of patients being consistently supplied for the same indication based on the authority or streamlined code.
Full Report
